MSB 4.89% $1.07 mesoblast limited

Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L, page-248

  1. 309 Posts.
    lightbulb Created with Sketch. 103
    I have just read all comments below posted on the FDA website. Lassman Law firm on top of the game against approval of the Rynocil. They have already submitted TWO comments against the approval. I don't know they have constructive points but they have well presented
    https://beta.regulations.gov/document/FDA-2020-N-1539-0022/comment

    From MSB side will need something constructive, professional, and well-documented comment on FDA website before the 13th. I would like to know how many times Lassman Law firm had commented against the approval and FDA still approved that product.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.